PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Thermo Fisher Scientific Develops New GC-MS Method to Comply with Federal Workplace Guidelines - Thermo Fisher Scientific Inc. introduces a new method for the confirmation of amphetamines in urine in accordance with recently updated United States Substance Abuse and Mental Health Services Administration Guidelines (NYSE: TMO)
Thermo Fisher Scientific Develops New GC-MS Method to Comply with Federal Workplace Guidelines

 

NewswireToday - /newswire/ - Holmes Chapel, Cheshire, United Kingdom, 2010/09/14 - Thermo Fisher Scientific Inc. introduces a new method for the confirmation of amphetamines in urine in accordance with recently updated United States Substance Abuse and Mental Health Services Administration Guidelines (NYSE: TMO).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Thermo Fisher Scientific Inc., the world leader in serving science, introduces a new method for the confirmation of amphetamines in urine in accordance with recently updated United States Substance Abuse and Mental Health Services Administration (SAMHSA) Mandatory Guidelines for Federal Workplace Drug Testing Programs, implemented on the 1st May 2010. The recently launched Thermo Scientific ISQ single quadrupole gas chromatography-mass spectrometry (GC-MS) instrument can analyze a greater number of sympathomimetic amines in urine in line with these updated regulations. Further information on the new method is detailed in an application note, entitled “Analysis of an Expanded Panel of Sympathomimetic Amines in Urine using Single Quadrupole GC/MS”.

As part of the updated SAMHSA guidelines, multiple changes were made for the confirmation of amphetamine-class urine analysis. In addition to SAMHSA’s previously published guidelines for amphetamine and methamphetamine, three amphetamine-analog drugs were added to the panel, including 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyethylamphetamine (MDEA). The confirmatory cutoff concentration level for the regulated amphetamines has also been lowered from 500 ng/mL to 250 ng/mL. To enable its customers to comply with these changes, Thermo Fisher has developed a method for the confirmation and quantification of the extended sympathomimetic amine panel in human urine using the ISQ™ single quadrupole GC-MS. The method also complies with requirements outlined by the College of American Pathologists (CAP), the Society of Forensic Toxicologists (SOFT) and the European Workplace Drug Testing Society (EWDTS).

The new method offers broad linearity to cover a wide range of analyte concentrations, with R2 values of 0.9990 or higher for all analytes over the range of 25-25,000 ng/mL. It also offers excellent precision near the 250 ng/mL cutoff set out by SAMHSA and detection and quantification limits are set at 25 ng/mL, ensuring sensitive performance. Furthermore, the new method enables MDEA to elute at a retention time of less than five minutes, enabling increased productivity in high-throughput toxicology laboratories when confirming the five amphetamine-analog drugs now included in the revised SAMHSA guidelines.

The ISQ GC-MS is a highly robust and rugged system that provides high-throughput sample confirmatory analyses and 24/7 operation. The new ExtractaBrite™ removable ion source feature is designed to provide maximum uptime and productivity by extending the length of time between required source maintenance. As a result, the ISQ system offers simplified operation and maximum uptime for uninterrupted productivity across routine GC-MS applications including general forensics, forensic toxicology, food safety and environmental.

For more information on the new method and the Thermo Scientific ISQ single quadrupole GC-MS, please call +1 866 463 6522 or email analyze[.]thermofisher.com.

Thermo Scientific is part of Thermo Fisher Scientific, the world leader in serving science.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (thermofisher.com) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of more than $10 billion, we have approximately 35,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Thermo Fisher Scientific Develops New GC-MS Method to Comply with Federal Workplace Guidelines

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Scottpr.com 
+44 1477 539539 thermo[.]scottpr.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics
Sartorius Announces Expansion of Sartorius Stedim Cellca
Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
BD Integrating Technology, Expertise and Services to Provide Comprehensive Medication Management
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Intrinsic Executive Search Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)